Journal DOI 10.68956/dyh5-kwte

Creative Commons source reading · Multiple sclerosis and neuroimmunology

Transcriptomics and proteomics reveal a cooperation between interferon and T-helper 17 cells in neuromyelitis optica.

Agnieshka M Agasing; Qi Wu; Bhuwan Khatri; Nadja Borisow; Klemens Ruprecht; Alexander Ulrich Brandt; Saurabh Gawde; Gaurav Kumar; James L Quinn; Rose M Ko; Yang Mao-Draayer; Christopher J Lessard; Friedemann Paul; Robert C Axtell

Originally published in Nature communications · 2020-06-05

From the article

Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.

Abstract

Type I interferon (IFN-I) and T helper 17 (TH17) drive pathology in neuromyelitis optica spectrum disorder (NMOSD) and in TH17-induced experimental autoimmune encephalomyelitis (TH17-EAE). This is paradoxical because the prevalent theory is that IFN-I inhibits TH17 function. Here we report that a cascade involving IFN-I, IL-6 and B cells promotes TH17-mediated neuro-autoimmunity. In NMOSD, elevated IFN-I signatures, IL-6 and IL-17 are associated with severe disability. Furthermore, IL-6 and IL-17 levels are lower in patients on anti-CD20 therapy. In mice, IFN-I elevates IL-6 and exacerbates TH17-EAE. Strikingly, IL-6 blockade attenuates disease only in mice treated with IFN-I. By contrast, B-cell-deficiency attenuates TH17-EAE in the presence or absence of IFN-I treatment. Finally, IFN-I stimulates B cells to produce IL-6 to drive pathogenic TH17 differentiation in vitro. Our data thus provide an explanation for the paradox surrounding IFN-I and TH17 in neuro-autoimmunity, and may have utility in predicting therapeutic response in NMOSD.

Discussion

The complex interplay between IFN-I and TH17 cells plays a significant role in the pathology of certain autoimmune diseases, notably, MS, NMOSD, psoriasis, systemic lupus erythematosus and ulcerative colitis32. The ability of IFN-I to drive or inhibit inflammation relies on the disease context. IFN-β remains a widely prescribed treatment for MS. As a therapy, IFN-I reduces relapse rates and lesion formation in MS patients and a predominant theory behind its efficacy is through the inhibition of TH17 differentiation and function17.

Editorial reading guide

  • Which patient population and reference standard did the authors use?
  • Was the finding validated in a separate cohort, and how might patient selection affect it?